. "2011-06-01+02:00"^^ . "8"^^ . "2015-01-22+01:00"^^ . . . "neurodegeneration; cerebrospinal fluid; parkinsonian syndrome"@en . "2015-12-31+01:00"^^ . "8"^^ . . "1"^^ . . "neurodegeneration" . "1"^^ . . "Parkinsonsk\u00FD syndrom je charakterizov\u00E1n bradykinez\u00ED, klidov\u00FDm t\u0159esem, rigiditou a postur\u00E1ln\u00EDmi poruchami. Jeho nej\u010Dast\u011Bj\u0161\u00ED p\u0159\u00ED\u010Dinou (asi 80% p\u0159\u00EDpad\u016F) je idiopatick\u00E1 Parkinsonova nemoc. Ale tak\u00E9 cel\u00E1 \u0159ada dal\u0161\u00EDch neurodegenerativn\u00EDch onemocn\u011Bn\u00ED, jako nap\u0159. demence s Lewyho t\u011Bl\u00EDsky, progresivn\u00ED supranukle\u00E1rn\u00ED paral\u00FDza, multisyst\u00E9mov\u00E1 atrofie, kortikobaz\u00E1ln\u00ED degenerace a jin\u00E9., se mohou manifestovat parkinsonsk\u00FDm syndromem. Diferenci\u00E1ln\u00ED diagnostika mezi jednotliv\u00FDmi onemocn\u011Bn\u00EDmi je zna\u010Dn\u011B limitov\u00E1na. C\u00EDlem projektu bude u pacient\u016F s p\u0159\u00EDznaky parkinsonsk\u00E9ho syndromu a u v\u011Bkov\u011B identick\u00E9 kontroln\u00ED skupiny prov\u00E9st podrobn\u00E9 vy\u0161et\u0159en\u00ED s\u00E9ra a mozkom\u00ED\u0161n\u00EDho moku se stanoven\u00EDm hladin marker\u016F neurodegenerace, z\u00E1n\u011Btu, onkomarkr\u016F, ukazetel\u016F tk\u00E1\u0148ov\u00E9 destrukce a dal\u0161\u00EDch. Hladiny t\u011Bchto marker\u016F budou nad\u00E1le po odb\u011Bru srovn\u00E1v\u00E1ny s pr\u016Fb\u011Bhem onemocn\u011Bn\u00ED, jeho p\u0159\u00EDpadnou progres\u00ED \u010Di v\u00FDvoj v jin\u00E9 onemocn\u011Bn\u00ED. Z\u00EDskan\u00E9 informace by pot\u00E9 mohly v\u00E9st k ur\u010Den\u00ED mo\u017En\u00E9ho prediktivn\u00EDho faktoru ur\u010Duj\u00EDc\u00EDho diagn\u00F3zu onemocn\u011Bn\u00ED." . . "2014-03-21+01:00"^^ . . "0"^^ . "http://www.isvav.cz/projectDetail.do?rowId=NT12221"^^ . . . "Markers of neurodegeneration in differential diagnosis of parkinsonian syndrome"@en . . "Parkinson syndrome (PS) is characterised by bradykinesis, rest tremor, rigidity and postural instability. The most frequent cause (about 80%) is idiopatic Parkinson's disease. But also a number of other neurodegenerative diseases , e.g. Lewy body disease, progressive supranuclear palsy, multisystem atrophy, corticobasal degeneration etc., can manifest itself with PS. Differential diagnosis between individual diseases is highly limited. Project goal will be in case of patients with PS and age identical control group to do detailed examination of serum and cerebrospinal fluid with determination of levels of neurodegenerative markers, inflamattory markers, oncomarkers, histic destruction pointers and other. The levels of the markers we took will be from now on compared with the disease process, its possible progression or development in different diseases. Gathered information could be instrumental towards the asessment of possible predictive factor defining disease prediction."@en . "Markery neurodegenerace v diferenci\u00E1ln\u00ED diagnostice parkinsonsk\u00FDch syndrom\u016F" . . "NT12221" . . " cerebrospinal fluid" . . . . .